-$0.33 EPS Expected for Minerva Neurosciences Inc (NERV) This Quarter

Analysts expect that Minerva Neurosciences Inc (NASDAQ:NERV) will report earnings of ($0.33) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences posted earnings per share of ($0.24) in the same quarter last year, which suggests a negative year over year growth rate of 37.5%. The firm is scheduled to report its next earnings results on Monday, March 11th.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.28) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.48) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.07.

Several research firms recently commented on NERV. BidaskClub upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 26th. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Friday, November 9th. Finally, ValuEngine upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 23rd.

Shares of Minerva Neurosciences stock opened at $7.91 on Friday. The stock has a market cap of $303.59 million, a PE ratio of -7.32 and a beta of 1.57. Minerva Neurosciences has a twelve month low of $5.00 and a twelve month high of $12.95.

In related news, Director William F. Doyle purchased 4,000 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was bought at an average price of $9.88 per share, for a total transaction of $39,520.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $39,520. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Venture Associates L. Index III sold 15,444 shares of Minerva Neurosciences stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $12.35, for a total value of $190,733.40. The disclosure for this sale can be found here. In the last quarter, insiders purchased 10,600 shares of company stock valued at $103,920 and sold 106,717 shares valued at $1,326,610. Company insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC bought a new stake in Minerva Neurosciences in the second quarter worth about $135,000. Falcon Point Capital LLC lifted its stake in Minerva Neurosciences by 28.6% in the third quarter. Falcon Point Capital LLC now owns 27,933 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 6,209 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Minerva Neurosciences by 329.4% in the second quarter. Acadian Asset Management LLC now owns 32,060 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 24,594 shares during the last quarter. Alpine Woods Capital Investors LLC lifted its stake in Minerva Neurosciences by 150.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in Minerva Neurosciences by 38.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 65,567 shares of the biopharmaceutical company’s stock worth $541,000 after purchasing an additional 18,267 shares during the last quarter. Institutional investors own 75.09% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Read More: Diversification

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply